Oxford Nanopore Technologies Collaborates With Twist Bioscience to Launch Pharmacogenomics Beta Programme and Advance Personalised Medicine
Oxford Nanopore Technologies (Oxford Nanopore) today announced the launch of a new Pharmacogenomics (PGx) Beta Program to advance personalised medicine, combining Twist Bioscience’s next generation sequencing (NGS) target enrichment technology with Oxford Nanopore’s sequencing platform.
- Oxford Nanopore Technologies (Oxford Nanopore) today announced the launch of a new Pharmacogenomics (PGx) Beta Program to advance personalised medicine, combining Twist Bioscience’s next generation sequencing (NGS) target enrichment technology with Oxford Nanopore’s sequencing platform.
- The beta program aims to increase the diversity of genetic variants evaluated by Oxford Nanopore’s platform.
- “Our collaboration with Twist Bioscience underscores our commitment to advancing the possibility of personalised medicine through PGx by providing unambiguous genetic results in a single assay,” said Gordon Sanghera, CEO of Oxford Nanopore.
- “The exceptional uniformity of our sequencer agnostic workflows enables researchers around the world to advance scientific breakthroughs.”
For more information about the PGx Beta Program and other innovations from Oxford Nanopore Technologies, visit https://nanoporetech.com .